KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Assets (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Other Non-Current Assets for 13 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets fell 51.11% year-over-year to $8.9 million, compared with a TTM value of $8.9 million through Dec 2025, down 51.11%, and an annual FY2025 reading of $8.9 million, down 51.11% over the prior year.
  • Other Non-Current Assets was $8.9 million for Q4 2025 at Travere Therapeutics, down from $10.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $35.0 million in Q1 2021 and bottomed at $8.9 million in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $16.9 million, with a median of $11.8 million recorded in 2023.
  • The sharpest move saw Other Non-Current Assets surged 414.92% in 2021, then plummeted 69.08% in 2022.
  • Year by year, Other Non-Current Assets stood at $11.1 million in 2021, then dropped by 3.48% to $10.7 million in 2022, then decreased by 0.22% to $10.7 million in 2023, then surged by 70.36% to $18.2 million in 2024, then tumbled by 51.11% to $8.9 million in 2025.
  • Business Quant data shows Other Non-Current Assets for TVTX at $8.9 million in Q4 2025, $10.3 million in Q3 2025, and $19.6 million in Q2 2025.